Abemaciclib

• Breast Cancer (HR+/HER2-)
• Metastatic Breast Cancer
• Adjuvant Breast Cancer Treatment

Abemaciclib is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor used in the treatment of hormone receptor-positive, HER2-negative breast cancer. This targeted therapy represents a significant advancement in cancer treatment by specifically blocking proteins that promote cancer cell growth.

Mechanism of Action

Abemaciclib selectively inhibits CDK4 and CDK6, which are kinases involved in regulating the cell cycle. These enzymes, when complexed with D-type cyclins, phosphorylate the retinoblastoma protein (Rb), promoting cell cycle progression from G1 to S phase. By inhibiting CDK4/6, abemaciclib prevents Rb phosphorylation, causing G1 arrest and blocking cancer cell proliferation. Compared to other CDK4/6 inhibitors, abemaciclib shows greater selectivity for CDK4 over CDK6 and has the ability to cross the blood-brain barrier, potentially providing activity against brain metastases.

Available Formulations

Abemaciclib is available as oral tablets in four strengths: 50 mg, 100 mg, 150 mg, and 200 mg. The tablets are film-coated and should be swallowed whole. The medication can be taken with or without food, though taking with food may help reduce gastrointestinal side effects.

Medical Uses

Abemaciclib is approved for several indications in HR+/HER2- breast cancer: in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women and men; in combination with fulvestrant for disease progression following endocrine therapy; and as monotherapy for adults with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. It is also approved for adjuvant treatment in patients with high-risk early breast cancer. Clinical trials demonstrated significant improvements in progression-free survival across all indications.

Dosing Guidelines

The recommended dose varies by indication and combination therapy. When combined with endocrine therapy, the dose is 150 mg twice daily. For monotherapy, the dose is 200 mg twice daily. Doses should be taken approximately 12 hours apart. Dose reductions are available for managing adverse reactions, with recommended reductions to 100 mg twice daily and then 50 mg twice daily. Treatment continues until disease progression or unacceptable toxicity.

Important Safety Information

Abemaciclib can cause severe diarrhea, which occurs frequently and may require dose modification or discontinuation. Patients should begin antidiarrheal therapy at the first sign of loose stools and increase fluid intake. The medication can also cause neutropenia, requiring regular complete blood count monitoring. Interstitial lung disease and hepatotoxicity have been reported, necessitating monitoring of liver function tests. Venous thromboembolism risk is increased.

Drug Interactions

Abemaciclib is primarily metabolized by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) increase abemaciclib exposure and should be avoided; if unavoidable, reduce the dose. Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's Wort) decrease exposure and should be avoided. Grapefruit and grapefruit juice should also be avoided. The medication may increase concentrations of CYP3A4 substrates with narrow therapeutic indices.

Special Populations

Abemaciclib can cause fetal harm and is contraindicated during pregnancy. Women should use effective contraception during treatment and for 3 weeks after the last dose. Men with female partners of reproductive potential should use contraception during treatment and for 3 weeks after. The medication should not be used during breastfeeding. Patients with severe hepatic impairment require dose reduction. No dose adjustment is needed for renal impairment or in elderly patients based solely on age.